معرفی
Joshua LaBaer is a Professor and Executive Director of the Biodesign Institute at Arizona State University (ASU), leading the Virginia G. Piper Center for Personalized Diagnostics. He holds affiliations with the School of Molecular Sciences and the College of Health Solutions. His research focuses on personalized medicine, leveraging protein microarrays and proteomics to develop biomarkers for early detection of diseases like cancer and diabetes. He pioneered the Nucleic Acid Programmable Protein Array (NAPPA) technology, widely used in biomedical research.
Education: MD (1990) and PhD in Biochemistry & Biophysics (1989) from the University of California, San Francisco (UCSF), followed by residency at Brigham and Women’s Hospital and oncology fellowship at Dana-Farber Cancer Institute.
Research Interests: Personalized medicine, biomarker discovery, protein microarrays, and high-throughput proteomics. His work emphasizes translating molecular insights into clinical diagnostics, exemplified by the first saliva-based SARS-CoV-2 testing in the U.S. and leadership in NIH-funded studies on immune response to COVID-19.
Awards: 2020 Arizona Bioscience Leader of the Year Award. Grants include NIH funding for cancer biomarker research and biodosimetry systems. He chairs the Early Detection Research Network (EDRN) and serves on editorial boards of journals like Journal of Proteome Research.
Labs/Teams: Directs the Biodesign Clinical Testing Laboratory and collaborates with institutions globally. His lab integrates robotics, bioinformatics, and protein engineering to advance diagnostics and therapeutics.
